At MM&M's annual conference, panelists talked about how healthcare is moving toward value-based care and accelerating innovation
Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.
As with most drug pricing battles, patients yet again are caught in the crossfire.
PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.
As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.
This time around the M&A moves will be much bigger in scope, promising to reconfigure the complex and fragile healthcare payer/provider/patient ecosystem.
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws
Consumers younger than the age of 45 were most likely to use an app developed by their health plan.
CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.
Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health
What's holding back value-based pricing deals from moving beyond the pilot phase?
CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.
Express Scripts removes 64 branded drugs from 2018 formulary; wearable market can regain momentum, analysts say; FDA accepts Herceptin biosimilars for review
Experts say this means drugmakers need to find new ways to communicate the value of their products.
Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
One pharmacy director would like to see a lot more comparative data about new therapies.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.
But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.
The Ways In campaign was UnitedHealthcare's first consumer advertising effort.
The multichannel effort — UnitedHealthcare's inaugural consumer brand advertising campaign — launched in March 2015 with the TV commercial Our Song.
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?